^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis
Published date:
12/07/2021
Excerpt:
High sPD-L1 was significantly associated with worse OS (hazard ratio [HR] = 2.20; 95% CI: 1.59-3.05; p < 0.001) and PFS (HR = 2.42; 95% CI: 1.72-3.42; p < 0.001) in patients treated with immune checkpoint inhibitors (ICIs)….sPD-L1 is a potential predictive biomarker of lung cancer.
DOI:
https://doi.org/10.2217/fon-2021-0641
